Arsenal Capital Advisors LLC Takes Position in Intuitive Surgical, Inc. $ISRG

Arsenal Capital Advisors LLC purchased a new stake in Intuitive Surgical, Inc. (NASDAQ:ISRG) during the 4th quarter, Holdings Channel.com reports. The institutional investor purchased 1,281 shares of the medical equipment provider’s stock, valued at approximately $726,000.

Several other institutional investors and hedge funds have also modified their holdings of the business. Petersen Hastings Wealth Advisors Inc. acquired a new position in shares of Intuitive Surgical in the fourth quarter valued at about $779,000. Prestige Wealth Management Group LLC grew its stake in shares of Intuitive Surgical by 1,280.5% in the fourth quarter. Prestige Wealth Management Group LLC now owns 1,132 shares of the medical equipment provider’s stock valued at $641,000 after acquiring an additional 1,050 shares in the last quarter. Harvest Fund Management Co. Ltd grew its stake in shares of Intuitive Surgical by 37.0% in the fourth quarter. Harvest Fund Management Co. Ltd now owns 30,264 shares of the medical equipment provider’s stock valued at $17,140,000 after acquiring an additional 8,173 shares in the last quarter. Vise Technologies Inc. grew its stake in shares of Intuitive Surgical by 28.7% in the fourth quarter. Vise Technologies Inc. now owns 8,123 shares of the medical equipment provider’s stock valued at $4,600,000 after acquiring an additional 1,812 shares in the last quarter. Finally, Verus Capital Partners LLC grew its stake in shares of Intuitive Surgical by 19.6% in the fourth quarter. Verus Capital Partners LLC now owns 1,109 shares of the medical equipment provider’s stock valued at $628,000 after acquiring an additional 182 shares in the last quarter. 83.64% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research firms recently commented on ISRG. Barclays set a $651.00 price target on shares of Intuitive Surgical and gave the company an “overweight” rating in a research note on Thursday, April 23rd. Deutsche Bank Aktiengesellschaft reduced their price objective on shares of Intuitive Surgical from $440.00 to $366.00 and set a “sell” rating on the stock in a research note on Tuesday. HSBC reduced their price objective on shares of Intuitive Surgical from $653.00 to $604.00 and set a “buy” rating on the stock in a research note on Wednesday, April 22nd. BTIG Research reiterated a “buy” rating and set a $574.00 price objective on shares of Intuitive Surgical in a research note on Wednesday, April 22nd. Finally, TD Cowen reduced their price objective on shares of Intuitive Surgical from $660.00 to $585.00 and set a “buy” rating on the stock in a research note on Wednesday, April 22nd. Nineteen research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $573.63.

Insider Transactions at Intuitive Surgical

In other news, SVP Mark Brosius sold 645 shares of the stock in a transaction dated Monday, March 9th. The shares were sold at an average price of $485.01, for a total value of $312,831.45. Following the completion of the transaction, the senior vice president owned 1,613 shares of the company’s stock, valued at approximately $782,321.13. This represents a 28.57% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Gary Loeb sold 400 shares of the stock in a transaction dated Monday, May 11th. The stock was sold at an average price of $446.95, for a total transaction of $178,780.00. Following the completion of the transaction, the executive vice president directly owned 6,120 shares of the company’s stock, valued at $2,735,334. This trade represents a 6.13% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 7,448 shares of company stock valued at $3,224,404. 0.60% of the stock is owned by company insiders.

Intuitive Surgical Trading Up 0.8%

ISRG stock opened at $422.06 on Friday. The stock has a market capitalization of $149.48 billion, a P/E ratio of 51.16, a price-to-earnings-growth ratio of 3.34 and a beta of 1.46. Intuitive Surgical, Inc. has a 12 month low of $396.68 and a 12 month high of $603.88. The firm has a 50-day moving average price of $447.24 and a 200-day moving average price of $501.02.

Intuitive Surgical (NASDAQ:ISRG) last posted its earnings results on Tuesday, April 21st. The medical equipment provider reported $2.50 EPS for the quarter, topping analysts’ consensus estimates of $2.08 by $0.42. The firm had revenue of $2.77 billion during the quarter, compared to analysts’ expectations of $2.62 billion. Intuitive Surgical had a net margin of 28.15% and a return on equity of 15.98%. The business’s revenue for the quarter was up 23.0% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.81 earnings per share. As a group, equities analysts predict that Intuitive Surgical, Inc. will post 8.57 EPS for the current fiscal year.

Intuitive Surgical Profile

Intuitive Surgical, founded in 1995 and headquartered in Sunnyvale, California, is a medical technology company focused on the design, manufacture and service of robotic-assisted surgical systems. The company is best known for its da Vinci surgical systems, which enable minimally invasive procedures by translating a surgeon’s hand movements into finer, scaled motions of small instruments inside the patient. Intuitive’s business centers on supplying hospitals and surgical centers with systems, instruments and related technologies that aim to improve precision, visualization and control in the operating room.

In addition to its core surgical platforms, Intuitive markets a portfolio of reusable and disposable instruments, accessories, and proprietary software, and provides training, servicing and clinical support to its customers.